Company profile
BEAM THERAPEUTICS INC.
NASDAQ:BEAMBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RISTOGLOGENE AUTOGETEMCEL | phase1_2 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06735755 | phase1_2 | recruiting | 2024-12-06 | 2027-12-30 | Beam Therapeutics Inc. | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) |
| NCT05885464 | phase1_2 | active_not_recruiting | 2023-05-25 | 2026-12-01 | Beam Therapeutics Inc. | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
| NCT06389877 | phase1_2 | recruiting | 2024-06-19 | 2028-05-01 | Beam Therapeutics Inc. | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) |
| NCT05456880 | phase1_2 | active_not_recruiting | 2022-08-30 | 2028-02-01 | Beam Therapeutics Inc. | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease |
| NCT07304791 | phase1 | recruiting | 2025-10-27 | 2026-01-29 | Beam Therapeutics Inc. | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects |
FDA applications (0)
No records yet.